Education
About Us
Working with TipRanks
Follow Us
Praxis Precision Medicines (PRAX)
NASDAQ:PRAX
PRAX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$26.70 - $91.83
Previous CloseN/A
Volume51.58K
Average Volume (3M)450.77K
Market Cap
$1.12B
Enterprise Value$602.50M
Total Cash (Recent Filing)$301.27M
Total Debt (Recent Filing)$755.00K
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Nov 05, 2025EPS Estimate
-3.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.31
Shares Outstanding21,049,585
10 Day Avg. Volume386,398
30 Day Avg. Volume450,774
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.54
Enterprise Value/Revenue77.59
Enterprise Value/Gross Profit78.53
Enterprise Value/Ebitda-2.26
Forecast
1Y Price Target
$105.90Price Target Upside98.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Bulls Say, Bears Say
Bulls Say
Drug Designation And Pricing PotentialBoth relutrigine and elsunersen have Orphan Drug Designation and Rare Pediatric Disease Designation with the FDA, with promising results in studies and premium pricing potential.
Enrollment And Program CommitmentPRAX has raised its total projected enrollment to 1,000 participants, indicating a strong commitment to its Essential Tremor program.
Market Entry And ValuationAt a market cap of less than $900 million, PRAX's valuation is attractive with multiple opportunities that could collectively drive over $4 billion in peak sales.
Trial Results And Market PotentialTopline results from PRAX's Phase 3 trials for ulixacaltamide in Essential Tremor are expected to potentially trigger significant upside, as the condition affects around 7 million US patients in need of better treatment options.
Bears Say
Cash ReservesThe company has a limited cash runway, with approximately 1.5 years of cash left.
Futility Analysis ImpactA negative interim futility analysis was reported for Study 1 (parallel-group design), prompting PRAX to explore alternative analytical approaches.
Praxis Precision Medicines News
PRAX FAQ
What was Praxis Precision Medicines’s price range in the past 12 months?
Praxis Precision Medicines lowest stock price was $26.70 and its highest was $91.83 in the past 12 months.
What is Praxis Precision Medicines’s market cap?
Praxis Precision Medicines’s market cap is $1.12B.
When is Praxis Precision Medicines’s upcoming earnings report date?
Praxis Precision Medicines’s upcoming earnings report date is Nov 05, 2025 which is in 23 days.
How were Praxis Precision Medicines’s earnings last quarter?
Praxis Precision Medicines released its earnings results on Aug 04, 2025. The company reported -$3.31 earnings per share for the quarter, missing the consensus estimate of -$3.247 by -$0.063.
Is Praxis Precision Medicines overvalued?
According to Wall Street analysts Praxis Precision Medicines’s price is currently Undervalued.
Does Praxis Precision Medicines pay dividends?
Praxis Precision Medicines does not currently pay dividends.
What is Praxis Precision Medicines’s EPS estimate?
Praxis Precision Medicines’s EPS estimate is -3.44.
How many shares outstanding does Praxis Precision Medicines have?
Praxis Precision Medicines has 21,049,585 shares outstanding.
What happened to Praxis Precision Medicines’s price movement after its last earnings report?
Praxis Precision Medicines reported an EPS of -$3.31 in its last earnings report, missing expectations of -$3.247. Following the earnings report the stock price went down -5.546%.
Which hedge fund is a major shareholder of Praxis Precision Medicines?
Currently, no hedge funds are holding shares in PRAX
Praxis Precision Medicines Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$105.90 (98.84% Upside)
$105.90 (98.84% Upside)
Blogger Sentiment
Neutral
PRAX Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 111.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.3%
Last 30 Days ▲ 16.5%
Last 30 Days ▲ 16.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.05%
12-Months-Change
Fundamentals
Return on Equity
-60.98%
Trailing 12-Months
Asset Growth
2.67%
Trailing 12-Months
Company Description
Praxis Precision Medicines
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
PRAX Company Deck
PRAX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant advancements in the efficacy of vormatrigine, strong execution of clinical trials, and a robust financial position. However, challenges remain in managing discontinuation rates and background therapy interactions.View all PRAX earnings summariesPRAX Stock 12 Month Forecast
Average Price Target
$105.90
▲(98.84% Upside)
Technical Analysis
ARS Pharmaceuticals
―
AbCellera Biologics
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Septerna, Inc.
―
Ownership Overview
10.71% Insiders
16.18% Mutual Funds
53.47% Other Institutional Investors
7.50% Public Companies and
Individual Investors